Crossject SA: Innovating Medical Injection Systems
Crossject SA, a France-based company operating in the Health Care Equipment & Supplies sector, is making significant strides in the development of medical injection systems. The company specializes in needle-free, pre-filled, single-use injection systems designed for intradermal, subcutaneous, and intramuscular applications. These systems are tailored for pharmaceutical companies and aim to enhance patient safety, compliance, and comfort.
As of August 27, 2025, Crossject SA’s close price stood at 1.52 EUR, with a market capitalization of 85,200,000 EUR. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of 2.75 EUR on October 21, 2024, and a low of 0.7199 EUR on April 10, 2025. The price-to-earnings ratio is currently at -5.387, reflecting the company’s ongoing investment in research and development.
Crossject SA’s product portfolio includes Zeneo, a prefilled and single-use device suitable for various injection types. This innovation is part of the company’s broader strategy to improve the delivery of well-known injectable drugs, encompassing both chemical and biologic formulations.
In addition to its product offerings, Crossject SA is actively engaged in research and development, with three drugs currently in the preclinical or clinical phase. This pipeline underscores the company’s commitment to advancing medical technology and expanding its impact on patient care.
Strategic industrial partnerships play a crucial role in Crossject SA’s operations. The company collaborates with Hirtenberger and Recipharm, leveraging these partnerships to enhance its technological capabilities and market reach.
Crossject SA is listed on the NYSE Euronext Paris, with its financial activities denominated in EUR. As the company continues to innovate and expand its product offerings, it remains a key player in the health care equipment and supplies industry, dedicated to improving patient outcomes through advanced medical technologies.